department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

BRIVARACETAM · pharmadog

pharmadog
drugs
BRIVARACETAM

drug · small molecule

patient view →

BRIVARACETAM

Marketedupdated 2mo ago

by UCB SA🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

indications

investigational

Epilepsy

targets

Synaptic vesicle glycoprotein 2A

all catalysts(6)

approval · 6

News(0)

no news has mentioned this drug yet

brand

BRIVARACETAM

trade names

Briviact, Briviact (in italy: nubriveo), Briviact (in italy: nubriveo)

generic

BRIVARACETAM

MOA

Synaptic vesicle glycoprotein 2A modulator

indication

Childhood Epilepsy

phase

marketed

BRIVARACETAM — FDA approval

BRIVARACETAM — FDA approval

BRIVARACETAM — FDA approval

BRIVARACETAM — FDA approval

BRIVARACETAM — FDA approval

BRIVARACETAM — FDA approval

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 9, 2030

~3.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Apr 9, 2030formulationUS 107296533.8y
Apr 9, 2030formulationUS 107296533.8y
Apr 9, 2030formulationUS 107296533.8y
Apr 9, 2030formulationUS 107296533.8y
Apr 9, 2030formulationUS 107296533.8y
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461
Feb 21, 2026compositionUS 6911461

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval28 co-mentions · 14 sources
tagSmall Molecule11 co-mentions · 11 sources
companyMicro Labs Ltd1 co-mentions · 1 sources

Trials studying BRIVARACETAM

phase3A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsyrecruitingn=120
phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsyactive not recruitingn=153
phase3A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsycompletedn=84
phase3Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsycompletedn=257
phase3A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsycompletedn=449
phase3A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalizationcompletedn=207
phase3A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizuresrecruitingn=70
—Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsyavailable

more trials →